Abstract
BackgroundVaccination by tumor neoantigens are promising immunotherapy by providing more tumor-reactive T cell pool, which could be boosted by anti-PD-1. Identification of neoantigens cognate to tumor-reactive tumor-infiltrating lymphocytes (TILs) is...
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have